Key Takeaways:
Regencell Bioscience Holdings Ltd. (NASDAQ: RGC), a traditional Chinese medicine developer with 12 employees and zero revenue, is facing a securities class action and a US Department of Justice investigation into trading in its ordinary shares, according to court filings and a company disclosure.
"The lawsuit contends that Regencell's public filings contained materially misleading statements about the Company's vulnerability to market manipulation and the financial risks posed by extraordinary share price volatility that bore no relationship to underlying business performance," Joseph E. Levi, a partner at Levi & Korsinsky, said.
RGC shares traded below $0.30 for most of the class period — Oct. 28, 2024 through Oct. 31, 2025 — before surging to $78 on June 17, 2025, a gain of more than 48,650% from its lows. The stock collapsed the following week and fell a further 18.56%, or $3.09, to $13.56 on Nov. 3, 2025, after the company disclosed it had received a DOJ subpoena. At its peak, Regencell carried a market valuation of approximately $14 billion despite having no approved products, no revenue, and annual research and development spending of roughly $1 million.
The gap between Regencell's market value and its business fundamentals creates potential fiduciary exposure for institutional holders. Fund managers and pension trustees who acquired RGC shares during the class period may face review obligations under ERISA and analogous fiduciary standards, the notice said. The lead plaintiff deadline is June 23, 2026, and the Private Securities Litigation Reform Act gives preference to movants with the largest financial interest, favoring institutional participants.
The complaint names Yat-Gai Au, Regencell's founder, chairman and chief executive officer, and Michelle Chan, the company's financial controller, as individual defendants. Au owned 88.6% of Regencell's outstanding shares as of June 30, 2025, giving him an outsized personal stake in the share price. Both officers signed Sarbanes-Oxley certifications appended to the 2024 annual report on Form 20-F, attesting that the filing contained no untrue statements of material fact. The complaint charges those certifications were false because they omitted known risks regarding market manipulation vulnerability and resulting regulatory exposure.
The DOJ subpoena, disclosed in an SEC filing on Oct. 31, 2025, indicated the department is investigating trading in Regencell's ordinary shares as well as corporate operational, financial and accounting matters. The company said it expects to continue incurring significant legal costs and may be required to pay fines, penalties, damages or settlement costs in excess of its insurance coverage.
The class action asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5. Securities class actions proceed on a contingency basis with no upfront cost to class members. The window to apply for lead plaintiff closes June 23, 2026, though class members who do not apply may still participate in any recovery.
The case underscores the risks of extreme valuation disconnects in small-cap biotech stocks. For institutional fiduciaries, the alleged omissions may trigger due diligence obligations under ERISA. Investors will watch for further DOJ disclosures and any court rulings on lead plaintiff appointment in the coming months.
This article is for informational purposes only and does not constitute investment advice.
